

Title (en)

Compositions and methods for the treatment and diagnosis of immune disorders

Title (de)

Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Autoimmunerkrankungen

Title (fr)

Compositions et méthodes pour le traitement et diagnostique de maladies autoimmunes

Publication

EP 1757621 A3 20080213 (EN)

Application

EP 06003809 A 19960301

Priority

- EP 96908594 A 19960301
- US 39863395 A 19950303
- US 48774895 A 19950607

Abstract (en)

[origin: EP1757621A2] The present invention relates to methods and compositions for the treatment of immune disorders, especially T helper (TH) cell and TH cell-like related disorders. First, genes are identified and described which are differentially expressed within and among TH cells and TH cell subpopulations. Second, genes are identified and described which are differentially expressed within TH cell subpopulations in TH cell subpopulation-related disorders. The modulation of the expression of the identified genes and/or activity of the identified gene products can be utilized therapeutically to ameliorate immune disorder symptoms and to modulate TH cell responsiveness, for example, responsiveness to antigen. Further, the identified genes and/or gene products can be used to diagnose individuals exhibiting or predisposed to such immune disorders. Still further, the identified genes and/or gene products can be used to detect TH cell responsiveness, for example, responsiveness to antigen.

IPC 8 full level

A01K 67/027 (2006.01); **C07H 21/00** (2006.01); **A61K 31/00** (2006.01); **A61K 38/00** (2006.01); **A61K 38/17** (2006.01); **A61K 39/395** (2006.01); **A61K 48/00** (2006.01); **A61K 49/00** (2006.01); **A61P 3/08** (2006.01); **A61P 3/10** (2006.01); **A61P 11/06** (2006.01); **A61P 29/00** (2006.01); **A61P 31/04** (2006.01); **A61P 37/00** (2006.01); **A61P 37/02** (2006.01); **A61P 37/08** (2006.01); **B60G 13/00** (2006.01); **C07K 14/00** (2006.01); **C07K 14/52** (2006.01); **C07K 14/705** (2006.01); **C07K 14/725** (2006.01); **C07K 16/00** (2006.01); **C07K 16/24** (2006.01); **C07K 16/28** (2006.01); **C07K 16/42** (2006.01); **C07K 16/46** (2006.01); **C07K 19/00** (2006.01); **C12N 1/21** (2006.01); **C12N 5/00** (2006.01); **C12N 5/10** (2006.01); **C12N 7/01** (2006.01); **C12N 9/64** (2006.01); **C12N 15/00** (2006.01); **C12N 15/09** (2006.01); **C12N 15/85** (2006.01); **C12Q 1/68** (2006.01); **G01N 33/15** (2006.01); **G01N 33/50** (2006.01); **G01N 33/564** (2006.01)

CPC (source: EP US)

A01K 67/0275 (2013.01 - EP US); **A01K 67/0278** (2013.01 - EP US); **A61P 3/08** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **B60G 13/003** (2013.01 - EP US); **C07K 14/70503** (2013.01 - EP US); **C07K 16/2803** (2013.01 - EP US); **C07K 19/00** (2013.01 - EP US); **C12N 9/6467** (2013.01 - EP US); **C12N 9/6472** (2013.01 - EP US); **C12N 15/8509** (2013.01 - EP US); **C12Q 1/6809** (2013.01 - EP US); **A01K 2207/15** (2013.01 - EP US); **A01K 2217/00** (2013.01 - EP US); **A01K 2217/05** (2013.01 - EP US); **A01K 2217/052** (2013.01 - EP US); **A01K 2217/206** (2013.01 - EP US); **A01K 2217/30** (2013.01 - EP US); **A01K 2227/105** (2013.01 - EP US); **A01K 2227/50** (2013.01 - EP US); **A01K 2267/03** (2013.01 - EP US); **A01K 2267/0325** (2013.01 - EP US); **A01K 2267/0368** (2013.01 - EP US); **A01K 2267/0381** (2013.01 - EP US); **A01K 2267/0387** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US); **C07K 2319/00** (2013.01 - EP US); **C12N 2800/30** (2013.01 - EP US); **C12N 2830/00** (2013.01 - EP US); **Y02A 50/30** (2017.12 - EP US); **Y10S 424/81** (2013.01 - EP US); **Y10S 530/868** (2013.01 - EP US)

Citation (search report)

- [X] WO 9005541 A1 19900531 - UNIV MICHIGAN [US], et al
- [X] WO 9118626 A1 19911212 - US COMMERCE [US]
- [T] US 5576191 A 19961119 - GAYLE MARGIT [US], et al
- [X] WERENSKIOLD A K: "CHARACTERIZATION OF A SECRETED GLYCOPROTEIN OF THE IMMUNOGLOBULIN SUPERFAMILY INDUCIBLE BY MITOGEN AND ONCOGENE", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 204, no. 3, 1992, pages 1041 - 1047, XP002453048, ISSN: 0014-2956
- [X] KLEMENZ R ET AL: "SERUM- AND ONCOPROTEIN-MEDIATED INDUCTION OF A GENE WITH SEQUENCE SIMILARITY TO THE GENE ENCODING CARCINOEMBRYONIC ANTIGEN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 86, no. 15, 1989, pages 5708 - 5712, XP002453049, ISSN: 0027-8424
- [X] TOMINAGA S-I: "A PUTATIVE PROTEIN OF A GROWTH SPECIFIC COMPLEMENTARY DNA FROM BALB-C-3T3 CELLS IS HIGHLY SIMILAR TO THE EXTRACELLULAR PORTION OF MOUSE INTERLEUKIN 1 RECEPTOR", FEBS LETTERS, vol. 258, no. 2, 1989, pages 301 - 304, XP002091854, ISSN: 0014-5793
- [X] BERGERS GABRIELE ET AL: "Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 13, no. 5, 1994, pages 1176 - 1188, XP008084104, ISSN: 0261-4189
- [X] YOSHIDA KAZUKO ET AL: "Cell biological studies on IL-1 receptor like protein ST2 using specific monoclonal antibodies", CELL STRUCTURE AND FUNCTION, vol. 18, no. 6, 1993, & FORTY-SIXTH ANNUAL MEETING OF THE JAPAN SOCIETY FOR CELL BIOLOGY; MAEBASHI, JAPAN; OCTOBER 20-22, 1993, pages 631, XP008084142, ISSN: 0386-7196
- [X] YANAGISAWA K ET AL: "PRESENCE OF A NOVEL PRIMARY RESPONSE GENE ST2L, ENCODING A PRODUCT HIGHLY SIMILAR TO THE INTERLEUKIN 1 RECEPTOR TYPE 1", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 318, no. 1, February 1993 (1993-02-01), pages 83 - 87, XP002935708, ISSN: 0014-5793
- [DX] MOSMANN T R ET AL: "THE ROLE OF IL-10 IN CROSSREGULATION OF T-H1 AND T-H2 RESPONSES", IMMUNOLOGY TODAY, vol. 12, no. 3, 1991, pages A49 - A53, XP002905054, ISSN: 0167-5699
- [XA] RAMSDELL F ET AL: "Differential ability of the TH1 and TH2 T cells to express Fas ligand and undergo activation-induced cell death", INTERNATIONAL IMMUNOLOGY, vol. 6, no. 10, 1994, pages 1545 - 1553, XP001010209
- [XA] JAMES A. LEDERER: "Regulation of cytokine gene expression in T helper cell subsets", THE JOURNAL OF IMMUNOLOGY, vol. 152, no. 1, 1 January 1994 (1994-01-01), pages 77 - 86, XP002169668
- [PX] YOSHIDA K ET AL: "Studies on natural ST2 gene products in the human leukemic cell line UT-7 using monoclonal antihuman ST2 antibodies", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 14, no. 5, October 1995 (1995-10-01), pages 419 - 427, XP002101452, ISSN: 0272-457X

Cited by

US9382318B2; US9982054B2; US10227414B2; US11059895B2; US11965029B2

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

EP 1757621 A2 20070228; EP 1757621 A3 20080213; EP 1757621 B1 20110907; AT E328891 T1 20060615; AU 5178396 A 19960923; AU 718245 B2 20000413; CA 2214589 A1 19960912; DE 69636216 D1 20060720; DE 69636216 T2 20070419; EP 0813538 A1 19971229; EP 0813538 A4 20011031; EP 0813538 B1 20060607; ES 2264800 T3 20070116; JP H11501807 A 19990216; US 2003158399 A1 20030821; US 5721351 A 19980224; US 6066322 A 20000523; US 6066498 A 20000523; US 6084083 A 20000704; US 6156887 A 20001205; US 6204371 B1 20010320; US 6288218 B1 20010911; US 6414117 B1 20020702; US 6562343 B1 20030513; US 7172750 B2 20070206; WO 9627603 A1 19960912

DOCDB simple family (application)

EP 06003809 A 19960301; AT 96908594 T 19960301; AU 5178396 A 19960301; CA 2214589 A 19960301; DE 69636216 T 19960301; EP 96908594 A 19960301; ES 96908594 T 19960301; JP 52694996 A 19960301; US 25213102 A 20020920; US 31036799 A 19990512; US 39863395 A 19950303; US 46423199 A 19991215; US 48007095 A 19950607; US 48774895 A 19950607; US 60958396 A 19960301; US 82952597 A 19970328; US 93739997 A 19970925; US 93972997 A 19971003; US 9602798 W 19960301